DCSIMG
Co-morbidity of Insomnia
Sanofi Logo
Text Size – + |   FAQs  |  Site Map  |  Contact Us  |   Consumer Site
For U.S. Healthcare Professionals Only
AMBIEN CR (Zolpidem Tartrate Extended Release) Sleep Aid

FOR HEALTHCARE PROFESSIONALS

Give your patients
a good night's sleep...
FOR LESS

Share the AMBIEN CR Offer Card with your patients for up to $20* off each of their next 12 prescriptions.

Learn More
Skip Navigation Links

Co-morbidity of Insomnia

Email to Your Friend Send to a Friend   Print Print Page

There is a common association between insomnia and certain health conditions, specifically Generalized Anxiety
Disorder (GAD)14-17 and Major Depressive Disorder (MDD).14,18,21

Studies show that 90% of patients with Major Depressive Disorder (MDD)15,19,22 and 44% of those with Generalized Anxiety
Disorder (GAD)16 suffer from insomnia. A majority of these patients show sleep maintenance symptoms and pronounced functional impairment throughout the day.15,17,18

Although effective treatments for GAD and MDD are available, like SSRIs, those treatments alone may not sufficiently address the sleep difficulties that are often associated with the disorders.17-19,22,23

AMBIEN CR 2-layer extended release tablets have proven effective in treating insomnia in patients with both Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD).17,18,23

It’s important to note a troubling trend: only about half of those patients with increased risk for insomnia have initiated a conversation with their health care professional about their sleep problems.1,8,20

That means many of your patients who have trouble sleeping may not be expressing their concerns during doctor’s visits. So it’s important for the health care professional to initiate conversations about sleep quality and next day consequences.

Learn more about Insomnia & Depression

Learn more about Insomnia & Anxiety

Next: Insomnia & Depression

pagedivide

* Maximum benefit is $240 off, up to $20 off each prescription (up to 12 prescriptions), depending on your out-of-pocket costs. Not valid for patients participating in Medicare, Medicaid, government (public insurance) programs, or any private payor in the state of Massachusetts and where prohibited by law.

AMBIEN CR is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. AMBIEN CR is not indicated for the treatment of GAD or MDD.

Due to its rapid onset of action, patients should take AMBIEN CR right before going to bed and when ready for sleep.

IMPORTANT SAFETY INFORMATION

Patients should not take AMBIEN CR unless they are prepared to get a full night’s sleep (7 to 8 hours) to avoid residual effects. Until they know how it will affect their physical or mental performance upon awakening, patients should not drive or operate hazardous machinery after taking AMBIEN CR or any other sleep medication. Complex behaviors such as somnambulism, including driving or eating while not fully awake, with amnesia for the event, as well as abnormal behaviors such as being more outgoing or aggressive than normal, confusion, agitation, and hallucinations may occur. AMBIEN CR should not be taken with alcohol as it may increase these abnormal behaviors. Discontinuation of AMBIEN CR should be strongly considered for patients reporting such complex behaviors. Angioedema may occur in patients taking AMBIEN CR and in rare cases may be fatal. Patients who develop angioedema should not be rechallenged. In primarily depressed patients, worsening of depression, including risk of suicidal thoughts or actions, including completed suicides, have been reported. Therefore, AMBIEN CR should be administered with caution to patients exhibiting signs or symptoms of depression, in whom suicidal tendencies may be present and protective measures may be required. Intentional overdosage is more common in this group of patients; the least amount of drug that is feasible should be prescribed for the patient at any one time.The most commonly observed adverse events in controlled clinical trials were headache, somnolence, and dizziness.

Please refer to the full prescribing information.